Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
After three months, evaluate if the patient has achieved a weight loss of 5% or more in non-diabetic patients, or 3% or more in diabetic patients in line with the European guidelines for obesity management ( Future treatments and remaining research gaps Ongoing research in obesity pharmacotherapy continues to yield promising developments, with two treatments particularly relevant for their potential impact
Recognized for excellence Limitless Lifes superior product quality and researcher support is evidenced by their Dun and Bradstreet business rating
Differences between baseline and follow-up measures were analyzed using paired t -tests or Wilcoxon signed-rank tests for continuous variables and chi-squared or Fishers exact tests for categorical data
The issue is what happens when genuine interest in better energy, faster recovery, improved body composition, and higher quality of life gets met with hype instead of clinical guidance
"Pregnancy or intention to become pregnant were exclusion criteria in our trials with semaglutide in both obesity and type 2 diabetes
